91271-57-7

Basic information

• Product Name: Benzenemethanol, 4-[(diethylamino)methyl]-
• CAS NO: 91271-57-7
• Molecular Formula: C12H19NO
• Molecular Weight: 193.289
• Mol File: 91271-57-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 4-[(diethylamino)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 4-[(diethylamino)methyl]-(91271-57-7)
• EPA Substance Registry System: Benzenemethanol, 4-[(diethylamino)methyl]-(91271-57-7)

Safety Data

• Hazardous Substances Data: 91271-57-7(Hazardous Substances Data)

Usage

Type

Synthetic opioid analgesic

Use

Treat moderate to severe pain

Mechanism of Action

Binds to mu-opioid receptor in central nervous system, prevents transmission of pain signals

Additional Mechanism

Serotonin-norepinephrine reuptake inhibitor

Classification

Schedule IV controlled substance in the United States

Common Side Effects

Nausea, constipation, dizziness, drowsiness

Severe Side Effects

Seizures, serotonin syndrome

Factors Contributing to Severe Effects

High doses, combination with other serotonergic medications

Upstream product

• 17201-43-3 4-cyanobenzyl bromide 
• 855271-71-5 diethyl-(4-methoxymethyl-benzyl)-amine 
• 69293-74-9 p-(diethylaminomethyl)benzonitrile 
• 52889-83-5 1-(chloromethyl)-4-(methoxymethyl)benzene 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 68453-55-4 methyl 4-((diethylamino)methyl)benzoate 
• 128982-36-5 ethyl 4-[(diethylamino)methyl]benzoate 
• 84227-70-3 p-(diethylaminomethyl)benzylamine 
• 855272-02-5 diethyl-(4-bromomethyl-benzyl)-amine 

Downstream Products

• 82413-58-9 4-[(diethylamino)methyl]-benzaldehyde 

Relevant articles and documents

3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease

One of the main obstacles toward the discovery of effective anti-Alzheimer drugs is the multifactorial nature of its etiopathology. Therefore, the use of multitarget-directed ligands has emerged as particularly suitable. Such ligands, able to modulate different neurodegenerative pathways, for example, amyloid and tau cascades, as well as cognitive and neurogenic functions, are fostered to come. In this respect, we report herein on the first class of BACE-1/GSK-3β dual inhibitors based on a 3,4-dihydro-1,3,5-triazin-2(1H)-one skeleton, whose hit compound 1 showed interesting properties in a preliminary investigation. Notably, compound 2, endowed with well-balanced potencies against the two isolated enzymes (IC50 of 16 and 7 μM against BACE-1 and GSK-3β, respectively), displayed effective neuroprotective and neurogenic activities and no neurotoxicity in cell-based assays. It also showed good brain permeability in a pharmacokinetic assessment in mice. Overall, triazinone derivatives, thanks to the simultaneous modulation of multiple points of the diseased network, might emerge as suitable candidates to be tested in in vivo Alzheimer's disease models.

Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains

A series of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones were synthesized and tested for their antimalarial properties. These compounds showed remarkable anti-plasmodial activity in vitro especially against chloroquine-resistant strains. Their pot